Balyasny Asset Management
ACHL

Balyasny Asset Management’s Achilles Therapeutics ACHL Stock Holding History

Balyasny Asset Management’s Portfolio ACHL Stock Details ACHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-17,059
Closed -$39K – 3322
2022
Q3 		$39K Buy
+17,059
New +$48.3K ﹤0.01% 2500

Other funds holding ACHL

SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Balyasny Asset Management's ACHL Position: Q4 2022 in Review

Balyasny Asset Management sold out of Achilles Therapeutics (ACHL) in Q4 2022, closing a stake of 17,059 shares — an estimated $39K sold.

Balyasny Asset Management first reported a position in ACHL in Q3 2022 and held it in 1 quarter. The position peaked at $39K in Q3 2022. 23 funds tracked by Wall St. Rank hold ACHL as of Q4 2022.

  • Balyasny Asset Management reported no remaining Achilles Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Balyasny Asset Management sold 17,059 Achilles Therapeutics shares in Q4 2022, an estimated $39K.
  • Balyasny Asset Management first reported a position in Achilles Therapeutics in Q3 2022 and held it in 1 quarter.
  • Balyasny Asset Management's Achilles Therapeutics position peaked at $39K in Q3 2022.
  • 23 funds tracked by Wall St. Rank held Achilles Therapeutics as of Q4 2022.

Based on Balyasny Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.